CHRS Coherus BioSciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CHRS

Price (delayed)

$2.03

Market cap

$228.81M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.53

Enterprise value

$604.62M

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings ...

Highlights
Coherus BioSciences's EPS has increased by 33% YoY and by 3.4% QoQ
The revenue rose by 22% year-on-year and by 22% since the previous quarter
The net income is up by 18% YoY but it is down by 10% from the previous quarter
Coherus BioSciences's quick ratio has decreased by 47% YoY and by 21% QoQ
The equity has contracted by 45% from the previous quarter and by 41% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.coherus.com/
Peers: AGEN AMGN RGEN

Key stats

What are the main financial stats of CHRS
Market
Shares outstanding
112.71M
Market cap
$228.81M
Enterprise value
$604.62M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.35
Earnings
Revenue
$257.24M
EBIT
-$197.73M
EBITDA
-$191.46M
Free cash flow
-$174.33M
Per share
EPS
-$2.53
Free cash flow per share
-$1.85
Book value per share
-$1.74
Revenue per share
$2.73
TBVPS
$5.93
Balance sheet
Total assets
$629.6M
Total liabilities
$823.03M
Debt
$478.7M
Equity
-$193.43M
Working capital
$143.86M
Liquidity
Debt to equity
-2.47
Current ratio
1.43
Quick ratio
1.14
Net debt/EBITDA
-1.96
Margins
EBITDA margin
-74.4%
Gross margin
38.2%
Net margin
-92.5%
Operating margin
-79%
Efficiency
Return on assets
-45.6%
Return on equity
N/A
Return on invested capital
-29.1%
Return on capital employed
-66.4%
Return on sales
-76.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CHRS stock price

How has the Coherus BioSciences stock price performed over time
Intraday
5.18%
1 week
-1.93%
1 month
-11.74%
1 year
-72.97%
YTD
-39.04%
QTD
-15.06%

Financial performance

How have Coherus BioSciences's revenue and profit performed over time
Revenue
$257.24M
Gross profit
$98.25M
Operating income
-$203.2M
Net income
-$237.89M
Gross margin
38.2%
Net margin
-92.5%
Coherus BioSciences's gross margin has decreased by 43% YoY and by 34% QoQ
The company's operating margin rose by 35% YoY and by 10% QoQ
The net margin has grown by 33% year-on-year and by 10% since the previous quarter
The gross profit has contracted by 30% YoY and by 20% from the previous quarter

Growth

What is Coherus BioSciences's growth rate over time

Valuation

What is Coherus BioSciences stock price valuation
P/E
N/A
P/B
N/A
P/S
0.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.35
Coherus BioSciences's EPS has increased by 33% YoY and by 3.4% QoQ
The equity has contracted by 45% from the previous quarter and by 41% YoY
The P/S is 79% below the 5-year quarterly average of 3.4 and 65% below the last 4 quarters average of 2.0
The revenue rose by 22% year-on-year and by 22% since the previous quarter

Efficiency

How efficient is Coherus BioSciences business performance
Coherus BioSciences's return on sales has increased by 37% YoY and by 9% QoQ
CHRS's return on invested capital is up by 32% year-on-year but it is down by 17% since the previous quarter
The return on assets is up by 15% year-on-year

Dividends

What is CHRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CHRS.

Financial health

How did Coherus BioSciences financials performed over time
The total assets is 24% less than the total liabilities
The current ratio has contracted by 48% YoY and by 23% from the previous quarter
Coherus BioSciences's quick ratio has decreased by 47% YoY and by 21% QoQ
The equity has contracted by 45% from the previous quarter and by 41% YoY
The debt to equity has grown by 30% from the previous quarter and by 29% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.